Garetatug Rezetecan

Approval Year

Substance Class	Protein Created by `admin` on `Wed Apr 02 11:18:41 GMT 2025` Edited by `admin` on `Wed Apr 02 11:18:41 GMT 2025`
Protein Type	MONOCLONAL ANTIBODY CONJUGATE
Protein Sub Type	IGG1\|KAPPA
Sequence Origin	HUMANIZED MOUSE
Sequence Type	COMPLETE
Record UNII	FD5J5RLD4E
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

SHRA1904

Preferred Name

English

Garetatug Rezetecan

Official Name

English

H-gamma1 heavy chain humanized (1-448) [VH (Homo sapiens IGHV1-3*01 (87.8%) -(IGHD) -IGHJ4*01 (92.9%) L123>T (113), CDR-IMGT [8.8.11] (26-33.51-58.97-107)) (1-118) -Homo sapiens IGHG1*01 (100%) G1m17,1 CH1 K120, CH3 D12, L14 (CH1 K120 (215) (119-216), hi

Common Name

English

immunoglobulin G1-kappa, anti-[Homo sapiens CLDN18 (claudin 18, claudin-18, surfactant associated protein J, SFTPJ) isoform 2], humanized monoclonal antibody; conjugated on an average of four cysteinyl residues to rezetecan, comprising a linker and a cam

Common Name

English

Immunoglobulin G1, anti-(human claudin-18 isoform A2) (human-Mus musculus monoclonal HRP00965 ?1-chain), disulfide with human-Mus musculus monoclonal HRP00965 ?-chain, dimer, reduced, tetrakis(thioether) with N-[6-(3-mercapto-2,5-dioxo-1-pyrrolidinyl)-1-

Common Name

English

garetatug rezetecan [INN]

Common Name

English

Code System Code Type Description

FDA UNII

FD5J5RLD4E

Created by admin on Wed Apr 02 11:18:41 GMT 2025 , Edited by admin on Wed Apr 02 11:18:41 GMT 2025

PRIMARY

INN

13530

Created by admin on Wed Apr 02 11:18:41 GMT 2025 , Edited by admin on Wed Apr 02 11:18:41 GMT 2025

PRIMARY

CAS

3023285-06-2

Created by admin on Wed Apr 02 11:18:41 GMT 2025 , Edited by admin on Wed Apr 02 11:18:41 GMT 2025

PRIMARY

Glycosylation Type

MAMMALIAN

Glycosylation Link Type	Site
N	1_298
N	2_298

Related Record Type Details


					FUV56ZH0GB

DNA TOPOISOMERASE 1

TARGET -> INHIBITOR

Interaction Type:

PRECLINICAL

Amount:


					9QF4QB7XAX

Garetatug

PARENT -> CONJUGATE

Amount:


					O86SW5D7BQ

CLAUDIN 18 SPLICE VARIANT 2

TARGET->LIGAND

Amount:

Related Record Type Details


					FD5J5RLD4E

Garetatug Rezetecan

ACTIVE MOIETY

Interaction Type:

PRECLINICAL

Amount:

Structural Modifications

Modification Type	Location Site	Location Type	Residue Modified	Extent	Fragment Name	Fragment Approval
AMINO ACID REMOVAL	[1_448] [2_448]	C-TERMINUS	K	Amount:	LYSINE	K3Z4F929H6
AMINO_ACID_SUBSTITUTION		SITE_SPECIFIC	C	Amount:	UNSPECIFIED SUBSTANCE	a9e52966 (not in database)

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
MOL_WEIGHT:NUMBER(CALCULATED)	CHEMICAL

Molecular Formula	CHEMICAL